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in TGF-b1–induced type I collagen gene transcription. TheseThe transforming growth factor-b/SMAD signaling pathway
findings raise the possibility that SMAD signaling plays a roleis present and functional in human mesangial cells.
in glomerular matrix accumulation.Background. Transforming growth factor-b (TGF-b) signals
through a unique set of intracellular proteins, called SMADs,
that have been characterized mainly in transient overexpres-
sion systems. Because several models of glomerulosclerosis Glomerulosclerosis, a scarring process involving extra-suggest a role for TGF-b in the extracellular matrix accumula-
cellular matrix (ECM) accumulation and structural col-tion, we sought to characterize the role of SMAD proteins in
lapse, is considered to be the final pathway leading tomediating TGF-b1 responses in a more physiological system
using nontransformed human mesangial cells. the loss of renal function in several kidney diseases.
Methods. Endogenous SMAD expression and its modula- Disease progression has been attributed to mechanical
tion by TGF-b1 were evaluated by Western and Northern blot factors such as hyperfiltration and to a variety of media-analyses. Phosphorylation of Smad2 and Smad3 was deter-
tors, including growth factors, cytokines, lipids, and eico-mined by both phospholabeling and immunoblot. SMAD func-
sanoids derived from circulating or glomerular cells [1].tion and its role in type I collagen transcription were investi-
gated in cotransfection experiments using promoter-luciferase Although significant progress has been made in under-
reporter gene constructs. standing the role of these factors in stimulating mesangial
Results. Cultured human mesangial cells express Smad2, cell proliferation and net ECM accumulation, little infor-Smad3, and Smad4 proteins. TGF-b1 down-regulated Smad3
mation is available regarding the mechanisms by whichmRNA and protein expression, respectively, after 4 and 24
these factors affect matrix turnover.hours of treatment, whereas Smad2 and Smad4 were less af-
fected. Both Smad2 and Smad3 were phosphorylated in re- Clinical studies have associated transforming growth
sponse to TGF-b1 beginning at 5 minutes, with maximal phos- factor-b (TGF-b) with glomerular matrix accumulation
phorylation at 15 minutes, and decreasing phosphorylation by in diabetic nephropathy, focal segmental glomeruloscle-2 hours. Smad2/3 and Smad4 coimmunoprecipitate only after
rosis, and IgA glomerulonephritis [2–5]. Furthermore,TGF-b1 treatment. The activity of a transiently transfected,
all three defined mammalian TGF-b isoforms (TGF-b1,TGF-b–responsive construct, p3TP-Lux, was stimulated 3.6-
fold by TGF-b1. Overexpressed wild-type Smad3 increased basal TGF-b2, and TGF-b3) are expressed in the renal glomer-
luciferase activity, which was further stimulated by TGF-b1. A ulus [2]. In a rat model of glomerulonephritis, increased
dominant negative mutant form of Smad3 lacking the C-termi- TGF-b expression is associated with increased plasmino-
nal serine phosphoacceptor sites (Smad3A) inhibited TGF-b1–
gen activator inhibitor-1 (PAI-1) synthesis, decreasedinduced luciferase activity. TGF-b1 also increased the activa-
plasminogen activator activity [6], and elevated matrixtion of an a2(I) collagen promoter-luciferase reporter construct
deposition [7]. In vitro, we and others have shown thattransfected into mesangial cells. This activation was inhibited
by cotransfection with the Smad3A mutant. TGF-b induces type I and type IV collagen and fibronec-
Conclusions. Smad2, Smad3, and Smad4 are present and tin synthesis by human mesangial cells [8–10]. The stimu-
activated by TGF-b1 in human mesangial cells. The SMAD lation of mesangial cell fibronectin synthesis by throm-pathway is functional in these cells and appears to be involved
boxane [11] and of ECM accumulation by angiotensin II
[12] is blocked by the inhibition of TGF-b activity. Fur-
thermore, platelet-derived growth factor, which is associ-Key words: type I collagen, serine phosphoacceptor sites, luciferase,
glomerulosclerosis, extracellular matrix. ated with renal glomerular disease, may also stimulate
TGF-b production. Because many fibrogenic stimuli mayReceived for publication December 22, 1998
induce TGF-b synthesis or activation, TGF-b actionand in revised form April 14, 1999
Accepted for publication April 29, 1999 could represent a common pathway mediating glomeru-
losclerosis. 1999 by the International Society of Nephrology
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Despite the wealth of data implicating TGF-bs in glo- METHODS
merular matrix accumulation, little is known regarding Materials
how TGF-b influences mesangial cell function. TGF-b Reagents were purchased from the following vendors:
is the prototype of a family of cytokines, including activ- active, human recombinant TGF-b1 from R&D Systems
ins and bone morphogenetic proteins (BMPs), that plays (Minneapolis, MN, USA); mouse monoclonal anti-Flag
an important role in varied physiological activities such M2 antibody from Sigma (St. Louis, MO, USA); goat
as proliferation, apoptosis, differentiation, inflammation, polyclonal anti-Smad2/3 IgG (N-19), mouse monoclonal
tissue remodeling, and wound healing [13]. In contrast to anti-Smad4 (B-8), normal goat IgG, antigoat IgG-horse-
other growth factors that signal through tyrosine kinase radish peroxidase (HRP), and antimouse IgG-HRP from
receptors, members of the TGF-b superfamily transmit Santa Cruz Biotechnology (Santa Cruz, CA, USA); re-
combinant protein G-Sepharose and rabbit polyclonaltheir signal via heteromeric complexes of transmem-
antiphosphoserine antibody from Zymed Laboratoriesbrane serine/threonine kinases, the type I and type II
(South San Francisco, CA, USA); antirabbit IgG-HRPreceptors [14]. Upon ligand binding, the type II receptor
from Promega (Madison, WI, USA); luciferase andrecruits and phosphorylates type I receptor. Until re-
b-galatosidase assay systems from Promega; restrictioncently, the subsequent signaling events were unknown.
and modifying enzymes from Roche/Boehringer Mann-Genetic screens in Drosophila led to the identification
heim Biochemicals (Indianapolis, IN, USA), GIBCOof the Mothers against decapentaplegic (Mad) gene, the
BRL (Gaithersburg, MD, USA), or Promega; and theproduct of which is required for signaling by the BMP
rapid DNA ligation kit from Roche/Boehringer Mann-orthologue Decapentaplegic [15, 16]. Simultaneously, the
heim Biochemicals.Sma genes, whose products signal downstream of the
Caenorhabditis elegans TGF-b family ligand DAF-7, were Cell culture and treatments
identified [17]. Subsequent studies defined eight Mad- Human mesangial cells were isolated from glomeruli
related gene products, called SMADs, in vertebrates. by differential sieving of minced normal human renal
There are divided into three subgroups [18, 19]. Upon cortex obtained from anonymous surgery or autopsy
activation, the TGF-b family receptor complex induces specimens. Cells were grown in Dulbecco’s modified Ea-
phosphorylation of the pathway-restricted SMAD pro- gle’s medium (DMEM)/Ham’s F12 medium, supple-
teins: Smad1, Smad5, and Smad8 following activation by mented with 20% heat-inactivated fetal bovine serum
BMPs and Smad2 and Smad3 following activation by (FBS), glutamine, penicillin/streptomycin, sodium pyr-
TGF-bs or activins. In all cases, the phosphorylated, uvate, HEPES buffer, and 8 mg/ml insulin (GIBCO
pathway-restricted SMADs associate with Smad4, a com- BRL) as previously described [29]. Cells were confirmed
mon-mediator SMAD. These heteromeric complexes are to be mesangial by morphological criteria, by the pres-
ence of abundant actin microfilaments, and by the ab-translocated to the nucleus, where they regulate gene
sence of staining for cytokeratin and factor VIII-relatedtranscription by either association with DNA-binding
antigen. They were mycoplasma free and were used be-protein or direct binding to promoter sequences of target
tween passages 4 and 8. Cells were plated at an identicalgenes [20–24]. Smad6 and Smad7 [25–27] belong to the
density in 100 mm culture dishes (3 to 5 3 105 cells/dish).inhibitory SMADs and act as inhibitors of the TGF-b
Three to five days later, cells in fresh complete mediumfamily signaling pathway, probably by competitive inter-
were treated with 1 ng/ml active, human recombinantaction with the type I receptor or with Smad4 [25–28].
TGF-b1 [dilutions made from a 4 mg/ml stock solutionIn most cases, an analysis of the SMAD pathway has
in 4 mm HCl containing 1 mg/ml bovine serum albuminbeen derived from studies performed in overexpression
(BSA)] or with control vehicle for different time periodssystems using transformed cells. There are no data avail-
leading up to simultaneous harvest.
able regarding the presence and activation of these pro-
teins in kidney cells. In this study, we examined whether RNA isolation and Northern blot
nontransformed human mesangial cells express SMAD Total RNA was isolated by the single-step method of
proteins. We show that Smad2 and Smad3 are detected Chomczynski and Sacchi [30]. Northern blot experiments
in the cells at the mRNA and protein level. Both proteins were carried out as described previously [10]. Briefly,
are rapidly phosphorylated in response to TGF-b1. Us- after electrophoresis through a 1.2% agarose–1.1%
ing transient transfection experiments, we showed that formaldehyde gel, the RNA was transferred onto Magna-
the SMAD pathway activates transcription and that Graph nylon membranes (MSI, Westborough, MA,
Smad3 is involved in type I collagen gene activation. USA). Following prehybridization at 658C for four
These data define a functional SMAD signal transduc- hours, hybridization was performed overnight at 658C
with 106 CPM/ml cDNA probes. The probes were [32P]tion pathway in human mesangial cells.
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labeled by random priming using the Rediprime DNA tion of the bands on autoradiograms was performed us-
ing densitometric analysis.labeling kit (Amersham Pharmacia Biotech, Piscataway,
NJ, USA). After incubation, the blots were washed un-
Immunoprecipitation and phosphoserine detectionder stringent conditions and then exposed to x-ray film
(Eastman Kodak, Rochester, NY, USA) at 2808C for Cells plated in 150 mm dishes (0.75 3 106 cells/plate)
were cultured for four days. The morning of the experi-1 to 72 hours according to the intensity of the signal.
Autoradiograms were scanned with an Arcus II Scanner ment, the cells were switched to medium containing 1%
FBS and were then treated with 1 ng/ml TGF-b1 for(AGFA) in the transparency mode, and densitometric
analysis was performed using the NIH Image 1.61 pro- different time periods leading up to simultaneous har-
vest. The cells were rinsed twice with ice-cold PBS andgram for Macintosh. The same blots were successively
rehybridized with additional probes after confirming harvested in RIPA buffer containing protease inhibitors
and phosphatase inhibitors (1 mm sodium orthovana-complete stripping by exposing the blots to x-ray film.
cDNAs for human Smad2 [31], Smad3 [32], and Smad4 date, 50 mm sodium fluoride, and 40 mm b-glycero-
phosphate). Lysates were clarified by centrifugation at[33] were used. The signals obtained by hybridization
with SMAD probes were corrected for loading using 18,000 g for 20 minutes. One milligram of lysate protein
was immunoprecipitated overnight at 48C with 2 mg anti-the signal obtained with a bovine 28S ribosomal RNA
provided by Dr. H. Sage (University of Washington, Smad2/3 antibody (N-19) or normal goat IgG, followed
by precipitation with 40 ml protein G-Sepharose for 90Seattle, WA, USA). We found that a correction for load-
ing with 28S or glyceraldehyde-3-phosphate dehydroge- minutes at 48C. After four washes with complete RIPA
buffer, the immunoprecipitates were eluted by boilingnase yielded similar results [10].
for five minutes in 60 ml 2 3 SDS sample buffer (100
Preparation of cell lysates and Western blot analysis mm Tris/HCl, pH 6.8, 4% SDS, 0.2% bromophenol blue,
20% glycerol, 200 mm dithiothreitol). Twenty microlitersAt the end of the treatment, the cells were washed
twice with ice-cold phosphate-buffered saline (PBS) be- were electrophoresed through a 8 or 10% SDS-poly-
acrylamide gel electrophoresis gel and transferred ontofore being lyzed on ice in RIPA buffer [50 mm Tris/
HCl, pH 7.5, 150 mm NaCl, 1% Nonidet P-40, 0.5% a PVDF membrane. Blots were blocked overnight at
48C with 5% nonfat dry milk (for anti-Smad2/3) or 3%deoxycholate, 0.1% sodium dodecyl sulfate (SDS)] con-
taining protease inhibitors [1 mm phenylmethylsulfonyl BSA (for antiphosphoserine) in TBS-Tween, followed
by incubation with the anti-Smad2/3 antibody (0.2 mg/ml),fluoride (PMSF), 1 mm ethylenediaminetetraacetic acid
(EDTA), 1 mg/ml leupeptin, 1 mg/ml pepstatin, and 1 anti-Smad4 antibody (0.2 mg/ml), or antiphosphoserine
antibody (1 mg/ml) for two hours at room temperature.mg/ml aprotinin]. The cell lysates were centrifuged at
18,000 g for 20 minutes at 48C, and the supernatant was Immunoreactive bands were visualized as described ear-
lier in this article.collected. The protein content was determined by Brad-
ford protein assay (Bio-Rad, Hercules, CA, USA). Fresh
Transient transfection and luciferase assayor frozen cell lysates were analyzed by SDS-polyacryl-
amide gel electrophoresis (10% acrylamide gel). All sam- The day before the transfection, 8 3 104 cells were
seeded into six-well plates. Eighteen hours later, cellsples were prepared in the Laemmli reducing buffer (final
concentration: 50 mm Tris/HCl, pH 6.8, 2% SDS, 10% were transfected with 0.5 mg of p3TP-Lux, kindly pro-
vided by Dr. J. Massague [34], or 2378COL1A2-Lucglycerol, 0.1% bromophenol blue, 100 mm dithiothreitol)
and boiled for five minutes before loading. Gels were construct (discussed later in this article), together with
0.5 mg of the vector expressing the indicated Smad3blotted onto Immobilon-P (polyvinylidine difluoride;
PVDF) membranes (Millipore, Bedford, MA, USA). variants kindly provided by Drs. H.F. Lodish and X. Liu
[35] or the empty vector and 0.5 mg of CMV-SPORT-b-Membranes were blocked with 5% nonfat dry milk in
Tris-buffered saline (TBS)-Tween (0.1%) for one hour galactosidase (GIBCO-BRL) as a control of transfection
efficiency. We assayed different methods of transfection,at room temperature followed by incubation with the
primary antibody (anti-Smad2/3 antibody, N-19, 0.2 including electroporation and lipofection with liposomal
reagents or nonliposomal reagents. Only the lattermg/ml; anti-Smad4, 0.2 mg/ml; or anti-Flag M2 antibody,
1 mg/ml) for two hours at room temperature. The blots method was of low toxicity for the cells and gave repro-
ducible results (data not shown). Transfection was per-were washed three times in TBS-Tween or TBS for five
minutes, followed by incubation with the secondary anti- formed with the Fugene6 transfection reagent (Roche/
Boehringer Mannheim Biochemical) according to thebody conjugated with HRP for one hour at room temper-
ature. After washing, the blots were developed with manufacturer’s instructions. After three hours, TGF-b1
or control vehicle was added to the cells, and 24 hourschemiluminescence reagents according to the manufac-
turer’s protocol (LuminoGLO Reagent and Peroxide; later, cells were harvested in 300 ml reporter lysis buffer
(Promega). Luciferase activity in 200 ml cell lysates wasNew England Biolabs, Beverly, MA, USA). Quantita-
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Fig. 1. Smad2 and Smad3 expression in human mesan-
gial cells. Identical amounts (100 mg) of human mesangial
cell lysate were loaded onto five lanes of a 10% SDS-
PAGE gel. After electrophoresis and transfer onto a
PVDF membrane, each lane was immunoblotted with
the anti-Smad2/3 antibody (N-19) alone (2) or with the
antibody that was preincubated overnight at 48C with
the indicated peptide. N19 (Santa Cruz), peptide corre-
sponding to amino acids 2 to 20 mapping within the
N-terminal part of Smad2; I-20 (Santa Cruz), peptide
corresponding to amino acids 145 to 164 within the
N-terminal part of Smad3; PKC (GIBCO-BRL), C-ter-
minal peptide corresponding to amino acids 577 to 592
of PKC z; S-20 (Santa Cruz), peptide corresponding to
amino acids 82 to 101 mapping at the N-terminal part
of Smad2. MW, molecular weight marker.
measured using the luciferase assay system (Promega) cess of peptide overnight at 48C and then used for immu-
noblotting. Preincubation with the N-19 peptide leadsin a Berthold Lumat luminometer. b-galactosidase assay
was performed in 96-well plates with 30 ml cell extracts. to disappearance of both bands, whereas the other pep-
tides do not affect the intensity of these bands (Fig. 1).Luciferase assay results were normalized for b-galac-
tosidase activity. In selected experiments, the expression These data suggest that the antibody specifically recog-
nizes Smad2 and Smad3 proteins. We then used thisof transfected constructs for Smad3 or Smad3A was eval-
uated by Western blot as described earlier in this article. technique to determine the effect of TGF-b1 on expres-
sion of these proteins. Human mesangial cells were
Plasmid constructs treated with 1 ng/ml TGF-b1 for different time periods
leading up to simultaneous harvest. Smad2 expressionThe 2378COL1A2-LUC construct containing the se-
quence 378 bp of the a2(I) collagen (COL1A2) promoter was slightly increased from one to eight hours of treat-
ment with TGF-b1, returned to baseline after 24 hours,and 58 bp of the transcribed sequence fused to the lucif-
erase (LUC) reporter gene was constructed as follows: and slightly decreased by 48 hours (ratio treated cells to
control cells, 0.74 6 0.09; Fig. 2A). In contrast, Smad3A BglII-HindIII fragment of the plasmid pMS-3.5/CAT
[36] was cloned into the BglII-HindIII sites of the pXP2 markedly decreased after 24 hours of incubation with
TGF-b1 and remained decreased for up to 48 hoursvector [37], which carries the luciferase reporter gene
without a promoter. The structure of the construct was (ratio treated cells to control cells, 0.55 6 0.13 at 24 hr
and 0.39 6 0.08 at 48 hr). Smad4 protein expression wasconfirmed by restriction mapping.
unchanged by TGF-b1 treatment (Fig. 2B). These results
Statistical analysis indicate that TGF-b1 modulates Smad3 expression in a
time-dependent manner, whereas it has little effect onStatistical differences between experimental groups
were determined by analysis of variance using InStat Smad2 and does not affect Smad4.
To investigate whether the changes observed in Smad32.03 software program for Macintosh. Values of P ,
0.05 were considered significant. protein levels are due to modulation of mRNA expres-
sion, cells were treated with 1 ng/ml TGF-b1 for different
time periods leading up to simultaneous harvest of total
RESULTS
RNA for Northern blot analysis. The transcript sizes
SMAD expression in human mesangial cells we observed are consistent with some reports in the
literature [25], but the size and intensity of the differentBecause most studies of SMAD signaling have been
performed in overexpression systems using transformed SMAD mRNAs appear to vary considerably with species
and tissue of origin. TGF-b1 induced a twofold decreasecells, we first examined whether nontransformed human
mesangial cells express these proteins. Immunoblot ex- in expression of Smad3 mRNA beginning between one
and four hours after the initiation of treatment (Fig. 3).periments were performed with an anti-Smad2 antibody
(N-19) that cross-reacts with Smad3. This antibody re- Smad3 mRNA expression continued to decrease for up
to 48 hours (ratio of 48-hr treated cells to control cells,vealed two bands: one at 58 kDa, the expected size of
Smad2, and one at 52 kDa, the expected size of Smad3 0.33 6 0.19). In contrast, mRNA levels of Smad2 and
Smad4 were not significantly affected by TGF-b1 treat-(Fig. 1). The specificity of these bands was determined
by preincubating the antibody with the peptide against ment. These results are consistent with the Western blot
data and suggest that TGF-b1 modulates Smad3 expres-which the antiserum was raised or with unrelated pep-
tides. The antibody was preincubated with a tenfold ex- sion at the mRNA level.
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Fig. 2. Time course of transforming growth fac-
tor-b1 (TGF-b1) effect on SMAD protein expres-
sion. Mesangial cells were treated with 1 ng/ml
TGF-b1 for the indicated time periods, leading
up to simultaneous harvest. Fifty micrograms of
cell lysates were electrophoresed onto a 10%
SDS-PAGE gel and transferred onto a PVDF
membrane, and the blot was developed with (A)
the anti-Smad2/3 antibody or (B) the anti-Smad4
antibody. A representative blot is shown at the
top. Results of densitometric analysis (means of
four different experiments using two mesangial
cell isolates) are shown at bottom. Symbols in A
are: (h) Smad2; ( ) Smad 3. Values are ex-
pressed as a ratio between treated and control
cells. *P , 0.05; **P , 0.005 by Welch t-test.
SMAD activation by transforming growth factor-b1 in treated with 1 ng/ml TGF-b1 for different time periods
human mesangial cells leading up to simultaneous harvest. Cells lysates were
analyzed as described earlier in this article. TGF-b1 in-These results indicate that mesangial cells express
duced rapid serine phosphorylation of both Smad2 andpathway-restricted SMAD proteins. In studies performed
Smad3, beginning within five minutes (Fig. 5). Maximalusing overexpressing cells, these SMADs are phosphory-
activation occurred at 15 minutes, and phosphorylationlated on C-terminal serine residues in response to recep-
levels decreased by 2 hours. Similar results were obtainedtor stimulation. We sought to determine whether or not
when 32P-labeled cells were stimulated with TGF-b1 be-TGF-b1 similarly activates SMAD proteins in nontrans-
fore immunoprecipitation with the anti-Smad2/3 anti-formed human mesangial cells. Cells were treated for 30
body and analysis of the resulting immunoprecipitatesminutes with 1 ng/ml TGF-b1 or with control vehicle,
by electrophoresis (data not shown).were lyzed, were immunoprecipitated with anti-Smad2/3
In overexpression studies, Smad4, the common-media-antibody, and were immunoblotted with antiphospho-
tor SMAD, binds to pathway-restricted SMADs thatserine antibody. As shown in Figure 4, Smad2 and Smad3
have been phosphorylated. The complex is then translo-are phosphorylated in response to TGF-b1. The expres-
cated to the nucleus. To determine whether these inter-sion of both proteins was not affected by a 30 minute
actions occur among endogenous SMADs in human mes-treatment with TGF-b1, as indicated by immunoblotting
angial cells, cells were treated with TGF-b1 for variouswith anti-Smad2/3 antibody. Normal goat IgG did not
periods of time before harvest, and the cell lysates wereprecipitate these two bands. Of note, the migration of
immunoprecipitated using anti-Smad2/3 followed by im-the Smad2 and Smad3 bands was slightly delayed in
munoblotting with anti-Smad4 or anti-Smad2/3 (Fig.the TGF-b1–treated group, probably because of their
6A). Smad2 and Smad3 were present at all time points.phosphorylation.
Little Smad4 coimmunoprecipitated with Smad2/3 underWe next examined the kinetics of Smad2 and Smad3
phosphorylation in response to TGF-b1. Cells were control condition. However, Smad4 was detected in im-
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Fig. 2B. (Continued)
munoprecipitates of Smad2/3 within 5 minutes after add- are replaced by three alanines [35], or the empty expres-
sion vector. TGF-b1 treatment led to a 3.6-fold increaseing TGF-b1, peaked at 15 to 30 minutes, and began to
in luciferase activity in cells cotransfected with the emptydecrease by 2 hours. This event does not reflect a change
expression vector (Fig. 7A). Cotransfection of the wild-in the amount of SMAD proteins that is present (Fig.
type Smad3 induced increased basal activity of the p3TP-6B). These results show that Smad4 transiently forms
Lux construct, and this activity was further increased incomplexes with Smad2/3 in mesangial cells treated with
response to TGF-b1 treatment. Surprisingly, Smad3ATGF-b1.
also caused a significant increase of luciferase activity in
the absence of TGF-b1, albeit not as strong as the effectThe SMAD pathway is functional in
of the wild-type protein. However, TGF-b1–inducedhuman mesangial cells
p3TP-Lux activity was almost completely abrogated byHaving shown that Smad2 and Smad3 are present in
Smad3A. To assure that both the wild-type and mutatednontransformed mesangial cells and are phosphorylated
Smad3 proteins were expressed at the same level, lysates
in response to TGF-b1, we investigated whether Smad3 of transfected cells were analyzed by Western blotting
contributes to transcriptional activation of a TGF-b– with the M2 Flag antibody. As shown in Figure 7B,
responsive promoter in transient transfection experi- similar amounts of Flag-N-Smad3 and Flag-N-Smad3A
ments. In these studies, we used the p3TP-Lux reporter are detected in transfected cells. Taken together, these
construct, which contains three tetradecanoyl phorbol results suggest that the SMAD pathway is functional in
acetate (TPA)-response elements and a small portion of human mesangial cells.
the plasminogen activator inhibitor-1 (PAI-1) promoter
SMADs are involved in type I collagen[34]. Cells were cotransfected with the p3TP-Lux con-
gene transcriptionstruct and either a vector expressing Flag-tagged Smad3
(Flag-N-Smad3), a dominant negative mutant of Smad3 We previously showed that TGF-b1 increases collagen
mRNA expression in human mesangial cells [10]. To(Flag-N-Smad3A) in which the three C-terminal serines
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Fig. 3. Effect of TGF-b1 on SMAD mRNA expression. Total RNA from cells treated as described in Figure 2 was subjected to denaturing
electrophoresis before transfer to a nylon membrane. The same blot was stripped and reprobed for expression of mRNA for Smad2, Smad3, and
Smad4. cDNA for 28S rRNA was used as a control for loading. (A) Representative experiment showing results of probing the same membrane
for Smad2, Smad3, and Smad4. The solid circle at the right of each autoradiogram shows the position of the 28S rRNA. (B) Results of densitometric
analysis for Smad 2 (h), Smad3 (e), and (s) Smad4. Values are expressed as the ratio between treated cells and control cells, after correction
for loading using 28S. Results are given as means 6 sem for four experiments. *P , 0.01 by Welch t-test.
determine whether this effect was due to increased tran-
scription rate and/or increased mRNA stability, cells
were treated with 1 ng/ml TGF-b1 or control vehicle in
the presence or absence of 250 ng/ml actinomycin D for
4, 8, and 24 hours. Total RNA was analyzed by Northern
blot. The rates of turnover for a1(I) and a2(I) collagen
mRNA were similar in control and TGF-b1–treated cells
(data not shown). This result suggested that TGF-b1
does not stabilize type I collagen transcripts, but rather
induces their expression by a transcriptional mechanism.
To evaluate whether TGF-b1 stimulates type I collagen
gene expression in mesangial cells and whether SMAD
proteins are involved in this process, we cloned the se-
quences from 2378 to 158 of the human a2(I) collagen
(COL1A2) promoter in front of the luciferase reporter
gene (2378COL1A2-LUC; discussed in the Methods
section). This promoter region has been shown to medi-
ate the TGF-b1 response in fibroblasts [38]. Cells were
cotransfected with the 2378COL1A2-LUC construct
and either the wild-type Smad3 expressing vector, the
Fig. 4. Phosphorylation of Smad2 and Smad3 in response to TGF-b1. Smad3A variant, or the empty expression vector. In cellsCells were treated with 1 ng/ml TGF-b1 or control vehicle for 30 min-
cotransfected with the empty vector, TGF-b1 induced autes. After immunoprecipitation with normal goat IgG (PI) or anti-
Smad2/3 antibody (Smad2/3), the complexes were electrophoresed 2.2-fold increase in luciferase activity (Fig. 8). Wild-type
through two parallel polyacrylamide gels, followed by immunoblotting.
Smad3 increased basal luciferase activity, but in the pres-The top blot was developed using antiphosphoserine antibody, and the
bottom blot was developed with an anti-Smad2/3 antibody (N-19). ence of TGF-b1, luciferase activity was further induced
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Fig. 5. Time course of TGF-b1-induced Smad2
and Smad3 phosphorylation. Cells were treated
with 1 ng/ml TGF-b1 for the indicated periods of
time leading up to simultaneous harvest and ana-
lyzed by immunoblotting as described in Figure 4.
Top blot, developed with antiphosphoserine anti-
body. Bottom blot, developed with anti-Smad2/3
antibody. PI, immunoprecipitation with normal
goat IgG. Similar results were obtained when the
cells were labeled with 32P-orthophosphate and im-
munoprecipitated with anti-Smad2/3 antibody, fol-
lowed by electrophoresis and autoradiography.
Fig. 6. Interaction between Smad2/3 and Smad4
after TGF-b1 treatment. Cells were treated as de-
scribed in Figure 5. (A) Cell lysates immunoprecipi-
tated with normal goat IgG (PI) or anti-Smad2/3
antibody (Smad2/3). Top blot developed with anti-
Smad4 antibody. Bottom blot developed with anti-
Smad2/3 antibody. (B) Whole cell lysates. The same
blot was developed with anti-Smad4 antibody (top
panel), followed by development with anti-Smad2/3
antibody (bottom panel). The asterisk (*) marks the
migration position of Smad4 in the blots developed
for Smad2/3.
1.8-fold. The Smad3-dominant negative mutant com- However, the cellular mechanisms of action of TGF-
b1 on ECM accumulation are not completely defined.pletely inhibited the TGF-b1–induced a2(I) collagen
Recent reports have identified SMAD proteins as spe-promoter activity. These results suggest that Smad3 is
cific mediators of TGF-b family signaling. In this study,involved in the stimulation of type I collagen gene tran-
we sought to examine the SMAD signaling pathway inscription by TGF-b1.
glomerular cells and its role in collagen gene expression.
We showed that nontransformed human mesangial cells
DISCUSSION express Smad2, Smad3, and Smad4. Both Smad2 and
Transforming growth factor-b1 has been suggested to Smad3 are rapidly phosphorylated and associate with
Smad4 in response to TGF-b1. The SMAD pathwayplay an important role in several glomerular diseases.
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Fig. 8. Inhibition of TGF-b1-induced a2(I) collagen promoter activa-
tion by a dominant negative mutant of Smad3. Cells were cotransfected
as described in Figure 7 using the 2378COL1A2-Luc reporter construct
instead of the p3TP-Lux. Luciferase and b-galactosidase activities were
measured 24 hours after TGF-b1 stimulation. Symbols are: (h) control;
( ) TGF-b1. Results are presented as the ratio between luciferase and
b-galactosidase activity and are expressed as the mean 6 sem of tripli-
cate wells from a representative experiment. Similar results were ob-
tained in three other experiments.
Fig. 7. Activation of a TGF-b-responsive promoter. Cells were cotran-
sfected with 0.5 mg p3TP-Lux reporter construct, and either 0.5 mg
of vector encoding wild-type Smad3 (Flag-N-Smad3), mutated Smad3
(Flag-N-Smad3A), or the empty expression vector (pEXL), along with
0.5 mg of CMV-SPORT-b-galactosidase vector as a control for transfec- of endogenous SMADs by TGF-b1 in nontransformed
tion efficiency. Transfected cells were treated with 1 ng/ml TGF-b1.
cells.After 24 hours, cells were lyzed, and luciferase and b-galactosidase
activities and protein contents were measured. (A) Luciferase activity In our experiments, whereas Smad2 and Smad4
was normalized to b-galactosidase activity and standardized as the fold mRNA expression was not affected by TGF-b1 treat-
changes relative to untreated cells cotransfected with the empty expres-
ment and Smad2 protein expression decreased slightlysion vector. Symbols are: (h) control; ( ) TGF-b1. Results are shown
as the mean 6 sem of triplicate wells from a representative experiments. at 48 hours, Smad3 protein was markedly decreased after
Similar results were obtained in two other experiments. (B) Cell lysates 24 hours of treatment with TGF-b1. This decrease was
were analyzed by immunoblot with the anti-Flag M2 antibody. E, empty
preceded by a decrease in Smad3 mRNA expression,expression vector; Sd3, Flag-N-Smad3; Sd3A, Flag-N-Smad3A.
suggesting that TGF-b1 inhibits Smad3 gene expression
and/or decreases the stability of its transcript. In contrast,
Nakao et al reported that in three different cells lines
mediates TGF-b1–induced mesangial cell gene transcrip- (mink epithelial cells, human anaplastic thyroid carci-
tion. Transient overexpression of Smad3 induces a2(I) noma cells, and keratinocytes), Smad2, Smad3, and
collagen promoter activity, whereas a mutated form of Smad4 mRNAs were not affected by TGF-b1 for up to
Smad3, in which three C-terminal serines are mutated 24 hours of treatment [25]. These differences may reflect
to alanines [35], inhibits the stimulation of a2(I) collagen the transformed nature of these cell lines and/or may
promoter activity by TGF-b1. These results define an represent cell-specific responses to TGF-b1. Several groups
active SMAD signaling pathway in human mesangial have reported the induction of mRNA expression for
cells. Although the TGF-b/SMAD signal transduction the inhibitory SMADs, Smad6 and Smad7, after TGF-b1
pathway has been dissected mainly in cells overexpress- or BMP treatment in various cell lines, suggesting that
ing receptors and/or SMADs, in cancer cell lines and inhibitory SMADs act in a negative feedback loop to
Xenopus embryos, very few studies have described this regulate the response to members of the TGF-b family
[25, 39, 40]. Our results suggest that down-regulationpathway in primary culture. This report is the first study
describing the phosphorylation and functional activation of Smad3 expression might also be part of a negative
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feedback loop controlling TGF-b1 signaling in human by TGF-b1 is uncertain. TGF-b may up-regulate the
activity of human collagen promoters in dermal fibro-mesangial cells. Thus, tight control of the cellular re-
sponse to TGF-b might result from a combination of blasts through interaction of a SMAD-containing com-
plex with the promoter region [47, 49]. However, theinduction of inhibitory SMADs and down-regulation of
pathway-restricted SMADs and might be cell-type spe- nature of this interaction is not known. Recent studies
have described direct binding of mammalian SMAD pro-cific. Additional mechanisms also could contribute to
the regulation of the TGF-b family signal transduction teins to DNA promoter sequences [22, 23, 50]. Alterna-
tively, several groups have shown a cooperative interac-pathway [41, 42].
The concept that SMADs may play a role in fibrogen- tion of Smad4, and Smad2 or Smad3, with other factors
such as the coactivators CREB-binding protein (CBP)esis is a relatively new one. Previously, abnormalities in
Smad2 and Smad4 (or DPC4) genes have been linked and p300 [51–53] and the transcription factors c-Jun and
c-Fos [54]. Whether SMAD proteins directly modulateto colorectal and pancreatic cancers, respectively [31,
43], suggesting a role as tumor suppressors. SMAD pro- gene expression by binding to the a2(I) collagen pro-
moter or associate with other DNA-binding collagen-teins also are important for early development and for
patterning in mammalian embryos, as well as in lung regulating proteins that have been described in fibro-
blasts [38, 55, 56] remains to be explored.branching morphogenesis in culture [44, 45]. However,
few studies have related the SMAD proteins to fibro- In summary, we have shown that SMAD proteins are
expressed in human mesangial cells and are activated ingenesis. Recent findings indicate that overexpression of
SMADs increases laminin expression in bovine corneal response to TGF-b1. Our results also suggest that the
SMAD signaling pathway is involved in a2(I) collagenendothelial cells [46] and a SMAD dominant negative
mutant decreases collagen promoter activity in human gene induction by TGF-b1. These findings raise the pos-
sibility that SMAD proteins might be implicated in glo-fibroblasts [47]. In the kidney, one preliminary report
describes the expression of SMAD proteins in transgenic merular matrix accumulation. Further investigation of
in vitro systems and in vivo models of kidney disease ismice overexpressing TGF-b receptors. All of these mice
develop progressive renal insufficiency, but a cohort of necessary to elucidate the potential role of the TGF-b/
SMAD signaling pathway in renal fibrosis.them showed a slower rate of progression, associated
with significantly increased expression of inhibitory
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